GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (STU:8BT) » Definitions » Cyclically Adjusted FCF per Share

BriaCell Therapeutics (STU:8BT) Cyclically Adjusted FCF per Share : €-4.15 (As of Jan. 2024)


View and export this data going back to 2016. Start your Free Trial

What is BriaCell Therapeutics Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

BriaCell Therapeutics's adjusted free cash flow per share for the three months ended in Jan. 2024 was €-0.425. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-4.15 for the trailing ten years ended in Jan. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 32.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 27.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of BriaCell Therapeutics was 32.50% per year. The lowest was 3.20% per year. And the median was 21.80% per year.

As of today (2024-05-14), BriaCell Therapeutics's current stock price is €1.99. BriaCell Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2024 was €-4.15. BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


BriaCell Therapeutics Cyclically Adjusted FCF per Share Historical Data

The historical data trend for BriaCell Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Cyclically Adjusted FCF per Share Chart

BriaCell Therapeutics Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.29 -13.08 -9.52 -6.11 -4.34

BriaCell Therapeutics Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.75 -4.45 -4.34 -3.73 -4.15

Competitive Comparison of BriaCell Therapeutics's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BriaCell Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



BriaCell Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BriaCell Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=-0.425/125.4675*125.4675
=-0.425

Current CPI (Jan. 2024) = 125.4675.

BriaCell Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201404 -0.864 98.920 -1.096
201407 -2.288 99.315 -2.890
201410 -0.028 99.473 -0.035
201501 -1.798 98.209 -2.297
201504 -0.911 99.710 -1.146
201507 -0.670 100.579 -0.836
201510 -0.954 100.500 -1.191
201601 -0.901 100.184 -1.128
201604 -0.887 101.370 -1.098
201607 -0.862 101.844 -1.062
201610 -0.951 102.002 -1.170
201701 -0.868 102.318 -1.064
201704 -1.944 103.029 -2.367
201707 -0.470 103.029 -0.572
201710 -2.381 103.424 -2.888
201801 -1.791 104.056 -2.160
201804 -1.938 105.320 -2.309
201807 -1.553 106.110 -1.836
201810 -1.767 105.952 -2.092
201901 -0.759 105.557 -0.902
201904 -2.537 107.453 -2.962
201907 -1.234 108.243 -1.430
201910 -1.065 107.927 -1.238
202001 -0.157 108.085 -0.182
202004 0.076 107.216 0.089
202007 -0.474 108.401 -0.549
202010 -0.063 108.638 -0.073
202101 -0.168 109.192 -0.193
202104 -0.985 110.851 -1.115
202107 -0.108 112.431 -0.121
202110 -0.101 113.695 -0.111
202201 -0.143 114.801 -0.156
202204 -0.291 118.357 -0.308
202207 -0.211 120.964 -0.219
202210 -0.232 121.517 -0.240
202301 -0.236 121.596 -0.244
202304 -0.313 123.571 -0.318
202307 -0.620 124.914 -0.623
202310 -0.432 125.310 -0.433
202401 -0.425 125.468 -0.425

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


BriaCell Therapeutics  (STU:8BT) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


BriaCell Therapeutics Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


BriaCell Therapeutics (STU:8BT) Business Description

Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (STU:8BT) Headlines

No Headlines